OncoCyte (OCX) Competitor Comparison
We are evaluating the key criteria listed to compare OncoCyte (OCX) against its competitors in the Biotechnology industry.
Market Capitalization
321 / 368Gross Profits
0 / 278Total Revenue
228 / 300EBITDA
89 / 337Free Cashflow
115 / 352Quick Ratio
291 / 357Earnings per Share
288 / 359Dividend yield
0 / 6Total Cash
311 / 358Performance 3 years
334 / 368Performance 5 years
288 / 368Performance 10 years
293 / 368Linearity 3 years
307 / 368Linearity 5 years
134 / 368Linearity 10 years
210 / 368Total Rank
341 / 368Dividend Rank
227 / 368Valuation Rank
223 / 368Piotroski Rank
300 / 368Muliplier Rank
170 / 368Total Revenue - OCX ranking 228 / 300
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.